With 18.7% of eligible adults reporting being up to date on lung cancer screening in a national survey, this was estimated to ...
New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer Acclaim-1 and Acclaim-3 ...
Tumor infiltrating lymphocyte (TIL) therapy uses immune cells harvested directly from a patient’s tumor.
A new report says too few eligible Americans are being checked for the country’s deadliest cancer before it spreads.
New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer Acclaim-1 and Acclaim-3 Clinical Trials Supported by FDA Fast Track ...
7h
If you experience these symptoms repeatedly, you could have lung cancer: “You should see a doctor”
A health campaign urges the public to pay closer attention to subtle warning signs that often go unnoticed in the earliest ...
Pharmaceutical Technology on MSN
USPTO grants patent to Genprex’s Reqorsa gene therapy
The US Patent and Trademark Office (USPTO) has granted a patent to Genprex for the use of its Reqorsa gene therapy in ...
New artificial intelligence technology is helping diagnose the U.S.’s most deadly cancer sooner, greatly improving the ...
Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.
Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells ...
Early detection is one of the best ways to improve lung cancer survival. It’s a message Northern Light Health is sharing in the fight against the leading cause of cancer death in the U.
Targeted therapies, guided by molecular testing, offer significant benefits, including fewer side effects and personalization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback